Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)’s share price rose 2.1% during mid-day trading on Thursday . The company traded as high as $3.96 and last traded at $3.94, with a volume of 989,450 shares trading hands. The stock had previously closed at $3.86.

SGYP has been the subject of a number of research analyst reports. Rodman & Renshaw reaffirmed a “buy” rating and issued a $15.00 price target on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. BTIG Research reissued a “buy” rating and issued a $11.00 price objective on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. Canaccord Genuity reissued a “buy” rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. Zacks Investment Research raised Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Monday, May 16th. Finally, Roth Capital reissued a “buy” rating on shares of Synergy Pharmaceuticals in a report on Monday, May 9th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Synergy Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $10.37.

The company’s market capitalization is $717.31 million. The firm has a 50 day moving average of $3.71 and a 200 day moving average of $3.64.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.28. On average, analysts anticipate that Synergy Pharmaceuticals Inc. will post ($1.01) EPS for the current year.

Other large investors have bought and sold shares of the company. California State Teachers Retirement System increased its stake in Synergy Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 185,372 shares of the biopharmaceutical company’s stock valued at $1,051,000 after buying an additional 3,251 shares in the last quarter. Morgan Stanley increased its stake in Synergy Pharmaceuticals by 6.8% in the fourth quarter. Morgan Stanley now owns 423,520 shares of the biopharmaceutical company’s stock valued at $2,401,000 after buying an additional 27,037 shares in the last quarter. Oxford Asset Management acquired a new stake in Synergy Pharmaceuticals during the fourth quarter valued at about $1,102,000. Finally, EAM Investors LLC acquired a new stake in Synergy Pharmaceuticals during the fourth quarter valued at about $3,672,000.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.